We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Noscapine Slows Growth and Spread of Prostate Cancer

By LabMedica International staff writers
Posted on 31 Mar 2010
Print article
Noscapine, a nonaddictive derivative of opium commonly used as an additive in cough medicines, has been shown to be effective in limiting the growth and spread of prostate cancer.

A cooperative effort united investigators from the Prostate Cancer Research and Education Foundation (PCREF; San Diego, CA, USA), the University of California, San Diego (UCSD; USA), and the MedInsight Research Institute (Baltimore, MD, USA). They worked with a model comprising nude mice that were injected with human prostate cancer cells.

In the study, the mice received oral noscapine or diluent (control) for 56 days, beginning seven days after inoculation with PC3 human prostate cancer cells; or noscapine for 70 days, beginning seven days before inoculation with the cancer cells.

Findings were published in the February 2010 issue of the journal Anticancer Research. They showed that pretreating the mice with noscapine before injecting them with prostate cancer cells resulted in the tumor growth rate being two-thirds smaller in the noscapine group. Furthermore, lung metastasis rates were 80% less in the mice pretreated with noscapine, and the noscapine group suffered no cancer-related weight loss – compared with significant weight loss in the non-noscapine group. Overall, pretreatment with noscapine gave anticancer benefits similar to those seen for treatment that was given after injection of cancer cells. In both cases, there were no signs of toxicity to normal cells or tissues.

"Based on our research so far, we believe that noscapine could be a very promising treatment to prevent recurrence in such cases due to its excellent safety record and oral bioavailability,” said first author Dr. Israel Barken, medical director of the PCREF. "PCREF is now seeking sponsorship for clinical data collection in postsurgery patients who are at high-risk of recurrence for their prostate cancer.”

Senior author Dr. Moshe Rogosnitzky, director of research at the MedInsight Research Institute, said, "It is MedInsight's belief that many effective treatments for this and other diseases can be selected from the vast armory of existing off-patent and unpromoted drugs. The results of this study, once confirmed in a clinical trial, are an example where we may yet again have an agent that not only has an envious safety record, but is already available for use today.”

Related Links:
Prostate Cancer Research and Education Foundation
University of California, San Diego
MedInsight Research Institute


Gold Supplier
SARS-CoV-2 IgM ELISA Kit
SARS-CoV-2 (COVID-19) IgM ELISA
New
Gold Supplier
NT-proBNP Quantitative Antigen Test
NT-proBNP-CHECK-1
New
5-Part Hematology Analyzer
Cellcount-60
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus

Print article

Channels

Molecular Diagnostics

view channel
Image: Sample prepared for next-generation DNA sequencing analysis (Photo courtesy of 123rf.com)

Next-Generation Sequencing Enables Diagnosis of Primary Immunodeficiency Disorders

The advent of next-generation sequencing (NGS) technology has enabled the diagnostic workup of patients suspected of having primary immunodeficiency disorders, which will have significant implications... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.